Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects

Yi Wen Chang, Chih Ming Su, Yen-Hao Su, Yuan Soon Ho, Hui Huang Lai, Hsin An Chen, Min Liang Kuo, Wen Chun Hung, Ya Wen Chen, Chih Hsiung Wu, Pai Sheng Chen, Jen Liang Su

研究成果: 雜誌貢獻文章

16 引文 斯高帕斯(Scopus)

摘要

Vascular endothelial growth factor receptor 3 (VEGFR-3) supports tumor lymphangiogenesis. It was originally identified as a lymphangiogenic factor expressed in lymphatic endothelial cells. VEGFR-3 was detected in advanced human malignancies and correlated with poor prognosis. Our previous studies show that activation of the VEGF-C/VEGFR-3 axis promotes cancer metastasis and is associated with clinical progression in patients with lung cancer, indicating that VEGFR-3 is a potential target for cancer therapy. In this study, we developed eight peptides targeting VEGFR-3. Two peptides strongly inhibited the kinase activity of VEGFR-3 and suppressed VEGF-C-mediated invasion of cancer cells. Moreover, these peptides abolished VEGF-C-induced drug resistance and tumor initiating cell formation. This study demonstrates the therapeutic potential of VEGFR-3-targeting peptides.

原文英語
頁(從 - 到)3823-3835
頁數13
期刊Oncotarget
5
發行號11
出版狀態已發佈 - 2014

    指紋

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

引用此

Chang, Y. W., Su, C. M., Su, Y-H., Ho, Y. S., Lai, H. H., Chen, H. A., Kuo, M. L., Hung, W. C., Chen, Y. W., Wu, C. H., Chen, P. S., & Su, J. L. (2014). Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects. Oncotarget, 5(11), 3823-3835.